Table 1 Baseline patient characteristics

From: A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours

Parameter

N =31

Sex, n (%)

 

 Male

20 (65)

 Female

11 (35)

Age, years

 

 Median (range)

59 (31–74)

 Mean (s.d.)

57 (11)

ECOG performance status, n (%)

 

 0

4 (13)

 1

26 (84)

 2

1 (3)

Diagnosis, n (%)

 

 Non-small cell lung cancer

19 (61)

 Malignant pleural mesothelioma

7 (23)

 Thymoma

2 (7)

 Alveolar soft part sarcoma

1 (3)

 Rectal cancer

1 (3)

 Unknown primary cancer

1 (3)

Prior therapy, n (%)

 

 Surgery

14 (45)

 Radiation

9 (29)

 Chemotherapy

29 (94)

  1. ECOG=Eastern Cooperative Oncology Group; s.d.=standard deviation.